Notebook

WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were

The Scientist Staff
Apr 26, 1998

WHAT FOLLOWS TAMOXIFEN? Warnings accompanied recent announcements from the University of Pittsburgh-based National Surgical Adjuvant Breast and Bowel Project and the National Cancer Institute in Bethesda, Md., that tamoxifen achieved a 45 percent reduction in the incidence of breast cancer compared to women who took a placebo in the Breast Cancer Prevention Trial. The 25-year-old drug still carries the risk of serious side effects for women over 50, officials said. But the overall results were a scientific boon, and the question now is, what safer compounds might follow? Genentech Inc. of South San Francisco is among several biotechnology firms working on ways to kill tumors by starving them of blood. Genentech's Dan Adelman is the lead clinician on Phase 2 clinical trials of anti-VEGF, a monoclonal antibody to block receptor binding of vascular endothelial growth factor (VEGF), which stimulates blood vessel development that can feed growing malignancies. Adelman is quick...

Interested in reading more?

Become a Member of

Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member?